Aligos Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock, par value, $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lawrence M. Blatt | 5.6% | 316,228 | SCHEDULE 13D, 2026-06-24 | 2026-06-16 |
| Sio Capital Management, LLC | 5.46% | 335,937 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| Woodline Partners LP | 4.4% | 239,362 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Adage Capital Management, L.P. | 3.9% | 210,000 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
Purpose of Transaction (Item 4)
Lawrence M. Blatt
General The Reporting Person intends to review his investments in the Issuer on a continuing basis. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Person may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. The Reporting Person may also enter into financial instruments or other agreements with institutional or other counterparties that would increase or decrease the Reporting Person's economic exposure with respect to their investment in the Issuer, which instruments or agreements may or may not affect the Reporting Person's beneficial ownership in securities of the Issuer. In addition, the Reporting Person, in his positions as President, Chief Executive Officer and a director of the Issuer, may engage in discussions with management, the Issuer's board of directors (the "Board"), other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-24; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 3.9% | SCHEDULE 13G/A |
| 2025-08-13 | Sio Capital Management, LLC | 5.49% | SCHEDULE 13G |
| 2025-08-14 | Woodline Partners LP | 9.8% | SCHEDULE 13G/A |
| 2025-11-14 | Woodline Partners LP | 8.7% | SCHEDULE 13G/A |
| 2026-02-11 | Sio Capital Management, LLC | 5.46% | SCHEDULE 13G/A |
| 2026-02-17 | Woodline Partners LP | 5.4% | SCHEDULE 13G/A |
| 2026-05-15 | Woodline Partners LP | 4.4% | SCHEDULE 13G/A |
| 2026-05-15 | Lawrence M. Blatt | 5.1% | SCHEDULE 13G |
| 2026-06-24 | Lawrence M. Blatt | 5.6% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Aligos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.